MedTrace Logo

Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study

NCT05373446 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-05-24

No results posted yet for this study

Summary

This is a Randomized, double-blind, Placebo-Controlled, Phase II Clinical Study to evaluate SSD8432 in combination with Ritonavir in asymptomatic infections or mild/common safety study of efficacy and safety in adult subjects with COVID-19.

Conditions

Interventions

DRUG

SSD8432 300mg

SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID

DRUG

SSD8432 750mg

SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID

DRUG

SSD8432Placebo

SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID

Sponsors & Collaborators

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yumei Yang, doctor · Jiangsu Xiansheng Pharmaceutical Co.,

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-20
Primary Completion
2022-10-31
Completion
2023-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05373446 on ClinicalTrials.gov